Intervention Review

You have free access to this content

Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp

  1. Helena Kastarinen1,*,
  2. Tuija Oksanen1,
  3. Enembe O Okokon2,
  4. Vesa V Kiviniemi3,
  5. Kristiina Airola4,
  6. Johanna Jyrkkä1,
  7. Tuomas Oravilahti1,
  8. Piia K Rannanheimo1,
  9. Jos H Verbeek5

Editorial Group: Cochrane Skin Group

Published Online: 19 MAY 2014

Assessed as up-to-date: 18 SEP 2013

DOI: 10.1002/14651858.CD009446.pub2


How to Cite

Kastarinen H, Oksanen T, Okokon EO, Kiviniemi VV, Airola K, Jyrkkä J, Oravilahti T, Rannanheimo PK, Verbeek JH. Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp. Cochrane Database of Systematic Reviews 2014, Issue 5. Art. No.: CD009446. DOI: 10.1002/14651858.CD009446.pub2.

Author Information

  1. 1

    Finnish Medicines Agency Fimea, Assessment of Pharmacotherapies, Fimea, Finland

  2. 2

    University of Calabar Teaching Hospital, Department of Community Medicine, Calabar, Cross River State, Nigeria

  3. 3

    Finnish Medicines Agency, Assessment of Pharmacotherapies, Kuopio, Finland

  4. 4

    Finnish Medicines Agency Fimea, Assessment of Medicinal Products, Fimea, Finland

  5. 5

    Finnish Institute of Occupational Health, Cochrane Occupational Safety and Health Review Group, Kuopio, Finland

*Helena Kastarinen, Assessment of Pharmacotherapies, Finnish Medicines Agency Fimea, P.O. Box 55, Fimea, 00034, Finland. helena.kastarinen@fimnet.fi.

Publication History

  1. Publication Status: New
  2. Published Online: 19 MAY 2014

SEARCH

[Figure 1]
Figure 1. Study flow diagram
[Figure 2]
Figure 2. 'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies
[Figure 3]
Figure 3. 'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study
[Analysis 1.1]
Analysis 1.1. Comparison 1 Steroid vs placebo, Outcome 1 Total clearance (at 4 weeks or less).
[Analysis 1.2]
Analysis 1.2. Comparison 1 Steroid vs placebo, Outcome 2 Total clearance (over 4 weeks).
[Analysis 1.3]
Analysis 1.3. Comparison 1 Steroid vs placebo, Outcome 3 Mean change in erythema score (at 4 weeks or less).
[Analysis 1.4]
Analysis 1.4. Comparison 1 Steroid vs placebo, Outcome 4 Erythema score (at 4 weeks or less).
[Analysis 1.5]
Analysis 1.5. Comparison 1 Steroid vs placebo, Outcome 5 Mean change in scaling score (at 4 weeks or less).
[Analysis 1.6]
Analysis 1.6. Comparison 1 Steroid vs placebo, Outcome 6 Scaling scores (at 4 weeks or less).
[Analysis 1.7]
Analysis 1.7. Comparison 1 Steroid vs placebo, Outcome 7 Mean change in pruritus score (at 4 weeks or less).
[Analysis 1.8]
Analysis 1.8. Comparison 1 Steroid vs placebo, Outcome 8 Pruritus scores (at 4 weeks or less).
[Analysis 1.9]
Analysis 1.9. Comparison 1 Steroid vs placebo, Outcome 9 Any adverse effect (at 4 weeks or less).
[Analysis 2.1]
Analysis 2.1. Comparison 2 Steroid vs calcineurin inhibitor, Outcome 1 Total clearance (at 4 weeks or less).
[Analysis 2.2]
Analysis 2.2. Comparison 2 Steroid vs calcineurin inhibitor, Outcome 2 Erythema score (at 4 weeks or less).
[Analysis 2.3]
Analysis 2.3. Comparison 2 Steroid vs calcineurin inhibitor, Outcome 3 Scaling score (at 4 weeks or less).
[Analysis 2.4]
Analysis 2.4. Comparison 2 Steroid vs calcineurin inhibitor, Outcome 4 Mean change in dandruff score (at 4 weeks or less).
[Analysis 2.5]
Analysis 2.5. Comparison 2 Steroid vs calcineurin inhibitor, Outcome 5 Any adverse effects at 4 weeks or less.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Steroid vs calcineurin inhibitor, Outcome 6 Any adverse effects (at 4 weeks or more).
[Analysis 3.1]
Analysis 3.1. Comparison 3 Steroid vs azole, Outcome 1 Total clearance (at 4 weeks or less).
[Analysis 3.2]
Analysis 3.2. Comparison 3 Steroid vs azole, Outcome 2 Total clearance (at 4 weeks or less, evaluated by participant).
[Analysis 3.3]
Analysis 3.3. Comparison 3 Steroid vs azole, Outcome 3 Erythema score (at 4 weeks or less).
[Analysis 3.4]
Analysis 3.4. Comparison 3 Steroid vs azole, Outcome 4 Mean change in erythema score at 4 weeks or less.
[Analysis 3.5]
Analysis 3.5. Comparison 3 Steroid vs azole, Outcome 5 Scaling score (at 4 weeks or less).
[Analysis 3.6]
Analysis 3.6. Comparison 3 Steroid vs azole, Outcome 6 Mean change in scaling score at 4 weeks or less.
[Analysis 3.7]
Analysis 3.7. Comparison 3 Steroid vs azole, Outcome 7 Pruritus score (at 4 weeks or less).
[Analysis 3.8]
Analysis 3.8. Comparison 3 Steroid vs azole, Outcome 8 Mean change in pruritus score at 4 weeks or less.
[Analysis 3.9]
Analysis 3.9. Comparison 3 Steroid vs azole, Outcome 9 Any adverse effects at 4 weeks or less.
[Analysis 3.10]
Analysis 3.10. Comparison 3 Steroid vs azole, Outcome 10 Any adverse effects at 4 weeks or more.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Mild steroid vs strong steroid, Outcome 1 Total clearance (at 4 weeks or less).
[Analysis 4.2]
Analysis 4.2. Comparison 4 Mild steroid vs strong steroid, Outcome 2 Total clearance (at 4 weeks or less, evaluated by participant).
[Analysis 4.3]
Analysis 4.3. Comparison 4 Mild steroid vs strong steroid, Outcome 3 Total clearance at 4 weeks or more.
[Analysis 4.4]
Analysis 4.4. Comparison 4 Mild steroid vs strong steroid, Outcome 4 Erythema score (at 4 weeks or less).
[Analysis 4.5]
Analysis 4.5. Comparison 4 Mild steroid vs strong steroid, Outcome 5 Scaling score (at 4 weeks or less).
[Analysis 4.6]
Analysis 4.6. Comparison 4 Mild steroid vs strong steroid, Outcome 6 Pruritus score (at 4 weeks or less).
[Analysis 4.7]
Analysis 4.7. Comparison 4 Mild steroid vs strong steroid, Outcome 7 Any adverse effects (at 4 weeks or less).
[Analysis 4.8]
Analysis 4.8. Comparison 4 Mild steroid vs strong steroid, Outcome 8 Any adverse effects (at 4 weeks or more).
[Analysis 5.1]
Analysis 5.1. Comparison 5 Steroid vs zinc pyrithione, Outcome 1 Scaling score (< 4 weeks).
[Analysis 6.1]
Analysis 6.1. Comparison 6 Desonide (mild steroid) vs Promiseb®, Outcome 1 Total clearance (at 4 weeks or less).
[Analysis 7.1]
Analysis 7.1. Comparison 7 Steroid vs calcipotriol, Outcome 1 Total clearance (at 4 weeks or less).
[Analysis 7.2]
Analysis 7.2. Comparison 7 Steroid vs calcipotriol, Outcome 2 Any adverse effects (at 4 weeks or less).
[Analysis 8.1]
Analysis 8.1. Comparison 8 Calcineurin inhibitor vs placebo, Outcome 1 Total clearance (at 4 weeks or less).
[Analysis 8.2]
Analysis 8.2. Comparison 8 Calcineurin inhibitor vs placebo, Outcome 2 Mean change in erythema score at 4 weeks or less.
[Analysis 8.3]
Analysis 8.3. Comparison 8 Calcineurin inhibitor vs placebo, Outcome 3 Mean change in scaling score at 4 weeks or less.
[Analysis 8.4]
Analysis 8.4. Comparison 8 Calcineurin inhibitor vs placebo, Outcome 4 Outcome: any adverse effects.
[Analysis 9.1]
Analysis 9.1. Comparison 9 Calcineurin inhibitor vs azole, Outcome 1 Erythema score (over 4 weeks).
[Analysis 9.2]
Analysis 9.2. Comparison 9 Calcineurin inhibitor vs azole, Outcome 2 Scaling score (over 4 weeks).
[Analysis 9.3]
Analysis 9.3. Comparison 9 Calcineurin inhibitor vs azole, Outcome 3 Any adverse effects (over 4 weeks).
[Analysis 10.1]
Analysis 10.1. Comparison 10 Calcineurin inhibitor vs zinc pyrithione, Outcome 1 Dandruff score (< 4 weeks).
[Analysis 11.1]
Analysis 11.1. Comparison 11 Lithium vs placebo, Outcome 1 Total clearance (over 4 weeks).
[Analysis 11.2]
Analysis 11.2. Comparison 11 Lithium vs placebo, Outcome 2 Any adverse effects at 4 weeks or more.
[Analysis 12.1]
Analysis 12.1. Comparison 12 Lithium vs azole, Outcome 1 Total clearance (< 4 weeks).
[Analysis 12.2]
Analysis 12.2. Comparison 12 Lithium vs azole, Outcome 2 Total clearance (at 4 weeks or more).